Celadon Pharmaceuticals Regulatory News (CEL)

15 May 2007 07:01

Celsis International PLC15 May 2007 CELSIS INTERNATIONAL PLC ("Celsis" or "the Company") Appointment of Non-Executive Directors 15 May 2007: Celsis International plc, the life sciences products and laboratoryservices company, today announces the appointment of Peter Jensen and NicholasBadman as Non-Executive Directors with effect from 15 May 2007. Peter Jensen, 56, a former corporate executive with GlaxoSmithKline/SmithKlineBeecham was most recently President of Worldwide Supply Chain Operations wherehe was responsible for a global network of GSK manufacturing sites. He hasexceptional experience in mergers and acquisitions, in both large corporate andmid-cap plc's, and represented SmithKline Beecham on the GSK merger IntegrationPlanning Committee. Peter has recently gained experience on a number of Boardsincluding Genetix, Domino Printing Sciences, Inion and the Newmarket RacecoursesTrust Limited. Nicholas Badman, 40, is currently the Chief Financial Officer of Evolutec Groupplc, a biopharmaceutical company developing drugs for allergy, inflammation andautoimmune disease. Mr Badman joined Evolutec prior to its IPO and wasinstrumental in its fundraising strategy. He has extensive financial experiencefollowing his previous position in investment banking with Citigroup (EuropeanHealthcare Investment Banking Team) and prior to this at HBSC Investment Bank.He qualified as a Chartered Accountant with Arthur Andersen. Mr Badman willalso be appointed to chair the Celsis Audit Committee. Jack Rowell, Non-Executive Chairman of Celsis, commented: "I am pleased to announce these two outstanding appointments which willsubstantially strengthen our Board. Peter Jensen brings with him a wealth ofpharmaceutical industry experience, especially in supply chain operations, whichwill provide invaluable knowledge for our business where we provide reduced timeand cost savings to our customers. We are also delighted that Nick Badman hasagreed to join the Board given his extensive financial and M&A experience. Bothappointments will be of great benefit to Celsis at this exciting time in ourdevelopment and we look forward to working with them as we continue to grow thecompany." There are no further details to be disclosed under the Continuing Obligationsprovisions of the Listing Rules (new rules LR9.6.13). Enquiries:Celsis International plc Tel: 01223 598 428Jay LeCoque, Chief Executive OfficerJenny Parsons, Corporate Communications Financial Dynamics Tel: 020 7831 3113Anna KeebleBen Atwell Notes to editors Celsis International plc Celsis International plc is a world leading provider of innovative life scienceproducts and laboratory services to the pharmaceutical, biopharmaceutical, andconsumer products industries through its three business areas; rapid detection,analytical and drug development services and ADME-Tox in vitro technologies.The company is listed on the London Stock Exchange (CEL.L). Each division of Celsis International plc has the capacity to deliversubstantial time and cost savings to its customers, in addition to ensuringproduct quality and safety for consumers. Using proprietary technology, therapid detection business provides diagnostic systems for the rapid detection ofcontamination. These systems provide significant economic value by reducing thetime it takes to test and release raw materials, in process and finished goodsto market. The analytical services division provides cost effective outsourcedlaboratory testing services to pharmaceutical and biopharmaceutical companies.Its comprehensive service offerings include a full spectrum of laboratoryservices from drug development and discovery to analytical chemistry andbiological sciences to stability storage and testing. In Vitro Technologies(IVT) supplies in vitro testing products to the pharmaceutical and biotechnologyindustries. IVT's in vitro products screen drug compounds early in thediscovery process, thereby reducing the time and cost of drug development. Further information can be found on its website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange